You just read:

Aytu BioScience Announces Study Initiation and First Patient Dosing in Prostate Cancer Clinical Study with Hybridyne Imaging Technologies for ProstaScint® in Combination with Hybridyne's ProxiScan™ Transrectal Camera

News provided by

Aytu BioScience, Inc.

06 Jun, 2016, 08:05 ET